Imperial College London
Portrait Picture

DR. DANIEL MUNBLIT

Faculty of Medicine, Department of Infectious Disease

Visiting Reader
 
 
 
//

Contact

 

daniel.munblit08 Website CV

 
 
//

Location

 

Paediatric Research UnitQueen Elizabeth the Queen Mother Wing (QEQM)St Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Greenhawt:2021:10.1016/j.jaip.2021.06.006,
author = {Greenhawt, M and Abrams, EM and Shaker, M and Chu, DK and Kahn, D and Akin, C and Alqurashi, W and Arkwright, P and Baldwin, JL and Ben-Shoshan, M and Bernstein, J and Bingeman, T and Blumchen, K and Byrne, A and Bognanni, A and Campbell, D and Campbell, R and Chagla, Z and Chan, ES and Chan, J and Comberiatti, P and Dribin, TE and Ellis, AK and Fleischer, DM and Fox, A and Frischmeyer-Guerrerio, PA and Gagnon, R and Grayson, MH and Horner, CC and Hourihane, J and Katelaris, CH and Kim, H and Kelso, JM and Lang, D and Ledford, D and Levin, M and Lieberman, J and Loh, R and Mack, D and Mazer, B and Mosnaim, G and Munblit, D and Mustafa, SS and Nanda, A and Oppenheimer, J and Perrett, KP and Ramsey, A and Rank, M and Robertson, K and Shiek, J and Spergel, JM and Stukus, D and Tang, ML and Tracy, JM and Turner, PJ and Whalen-Browne, A and Wallace, D and Wang, J and Wasserman, S and Witty, JK and Worm, M and Vander, Leek TK and Golden, DB},
doi = {10.1016/j.jaip.2021.06.006},
journal = {Journal of Allergy and Clinical Immunology: In Practice},
pages = {3546--3567},
title = {The risk of allergic reaction to SARS-CoV-2 vaccines and recommended evaluation and management: a systematic review, meta-analysis, GRADE assessment, and international consensus approach},
url = {http://dx.doi.org/10.1016/j.jaip.2021.06.006},
volume = {9},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Concerns for anaphylaxis may hamper SARS-CoV-2 immunization efforts. We convened a multi-disciplinary group of international experts in anaphylaxis comprised of allergy, infectious disease, emergency medicine, and front-line clinicians to systematically develop recommendations regarding SARS-CoV-2 vaccine immediate allergic reactions. Medline, EMBASE, Web of Science, the WHO global coronavirus database, and the grey literature (inception-March 19, 2021) were systematically searched. Paired reviewers independently selected studies addressing anaphylaxis after SARS-CoV-2 vaccination, polyethylene glycol (PEG) and polysorbate allergy, and accuracy of allergy testing for SARS-CoV-2 vaccine allergy. Random effects models synthesized the data to inform recommendations based on the GRADE approach, agreed upon using a modified Delphi panel. The incidence of SARS-CoV-2 vaccine anaphylaxis is 7.91 cases/million (n=41,000,000 vaccinations, 95%CI 4.02-15.59; 26 studies, moderate certainty), the prevalence of PEG allergy is 103 cases/million (95%CI 88-120; 2 studies, very low certainty), and the sensitivity for PEG skin testing is poor though specificity is high (15 studies, very low certainty). We recommend vaccination over either no vaccination or performing SARS-CoV-2 vaccine/excipient screening allergy testing for individuals without history of a severe allergic reaction to the SARS-CoV-2 vaccine/excipient, and a shared decision-making paradigm in consultation with an allergy specialist for individuals with a history of a severe allergic reaction to the SARS-CoV-2 vaccine/excipient. We recommend further research to clarify SARS-CoV-2 vaccine/vaccine excipient testing utility in individuals potentially allergic to SARS-CoV2 vaccines or their excipients.
AU  - Greenhawt,M
AU  - Abrams,EM
AU  - Shaker,M
AU  - Chu,DK
AU  - Kahn,D
AU  - Akin,C
AU  - Alqurashi,W
AU  - Arkwright,P
AU  - Baldwin,JL
AU  - Ben-Shoshan,M
AU  - Bernstein,J
AU  - Bingeman,T
AU  - Blumchen,K
AU  - Byrne,A
AU  - Bognanni,A
AU  - Campbell,D
AU  - Campbell,R
AU  - Chagla,Z
AU  - Chan,ES
AU  - Chan,J
AU  - Comberiatti,P
AU  - Dribin,TE
AU  - Ellis,AK
AU  - Fleischer,DM
AU  - Fox,A
AU  - Frischmeyer-Guerrerio,PA
AU  - Gagnon,R
AU  - Grayson,MH
AU  - Horner,CC
AU  - Hourihane,J
AU  - Katelaris,CH
AU  - Kim,H
AU  - Kelso,JM
AU  - Lang,D
AU  - Ledford,D
AU  - Levin,M
AU  - Lieberman,J
AU  - Loh,R
AU  - Mack,D
AU  - Mazer,B
AU  - Mosnaim,G
AU  - Munblit,D
AU  - Mustafa,SS
AU  - Nanda,A
AU  - Oppenheimer,J
AU  - Perrett,KP
AU  - Ramsey,A
AU  - Rank,M
AU  - Robertson,K
AU  - Shiek,J
AU  - Spergel,JM
AU  - Stukus,D
AU  - Tang,ML
AU  - Tracy,JM
AU  - Turner,PJ
AU  - Whalen-Browne,A
AU  - Wallace,D
AU  - Wang,J
AU  - Wasserman,S
AU  - Witty,JK
AU  - Worm,M
AU  - Vander,Leek TK
AU  - Golden,DB
DO  - 10.1016/j.jaip.2021.06.006
EP  - 3567
PY  - 2021///
SN  - 2213-2198
SP  - 3546
TI  - The risk of allergic reaction to SARS-CoV-2 vaccines and recommended evaluation and management: a systematic review, meta-analysis, GRADE assessment, and international consensus approach
T2  - Journal of Allergy and Clinical Immunology: In Practice
UR  - http://dx.doi.org/10.1016/j.jaip.2021.06.006
UR  - https://www.ncbi.nlm.nih.gov/pubmed/34153517
UR  - https://www.sciencedirect.com/science/article/pii/S2213219821006711?via%3Dihub
UR  - http://hdl.handle.net/10044/1/90017
VL  - 9
ER  -
Download